Market Size of Anthrax Treatment Industry
Study Period | 2021 - 2029 |
Base Year For Estimation | 2023 |
Forecast Data Period | 2024 - 2029 |
CAGR | 7.80 % |
Fastest Growing Market | Asia-Pacific |
Largest Market | North America |
Major Players*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Anthrax Treatment Market Analysis
The anthrax treatment market is expected to register a CAGR of 7.8% over the forecast period.
The COVID-19 pandemic caused disruptions in the supply chains and treatment protocols for pharmaceuticals around the world, which also influenced the global antibiotics and immunoglobulins specific to the anthrax market. On a global scale, however, it appeared infrequently in developed countries compared to developing and underdeveloped nations. For instance, as per the report published by the Annals of Medicine and Surgery in September 2022, Zimbabwe and southern Kenya have seen anthrax outbreaks with significant morbidity and low mortality during the COVID-19 pandemic. Initiatives undertaken within the countries to lower the spread of diseases have positively impacted the market's growth. For instance, telecommunications firms were employed by countries including Nigeria, Zambia, So Tomé and Principe, and Burkina Faso to promote the supply of information about preventative and control measures. Thus, there was a significant impact on the treatment of anthrax in developing regions during the pandemic that helped the market grow. As per the analysis, the reinstatement of the supply chains and healthcare facilities is another factor that is expected to contribute to the market under consideration eventually reaching its full potential in the post-pandemic phase.
Furthermore, the anthrax treatment market will show rapid growth due to the increase in research funding and the development of novel therapies for the treatment of anthrax. Along with the aforementioned considerations, the emergence of new anthrax animal cases in various regions also supports market expansion as human exposure to animal spores might result in anthrax.
The increasing number of novel developments for the innovative and effective treatment of anthrax is one of the major factors expected to boost the growth of the anthrax treatment market. There has been a surge in the development of novel therapies due to the rising threat of exposure to Bacillus anthracis among civilian populations and military forces. For instance, in December 2021, USAMRIID researchers found a way to prevent mice from contracting the lethal disease anthrax by altering an enzyme generated by the bacterium that causes it. Their conclusion could result in the development of new antibiotics for various bacterial illnesses as well as a potential therapeutic approach for multidrug-resistant anthrax strains. The growing threat of exposure has thus led to the development of new therapies for anthrax treatment, which will have a positive impact on the growth of the anthrax treatment market in the near future.
Similarly, the new cases of anthrax among animals influence the market as it spreads to humans through animal spores. For instance, according to the public notice published by the government of Sierra Leone in May 2022, new anthrax disease cases were discovered among animals in the northern district of Port Loko in the city of Sierra Leone, West Africa. This may increase the spread to humans and increase the demand for anthrax treatment, which is expected to drive the growth of the market during the study period.
However, the high cost associated with diagnostic treatment is expected to restrain the growth of the anthrax treatment market over the analysis period.
Anthrax Treatment Industry Segmentation
As per the scope of the report, anthrax is a harmful disease that affects both humans and animals. Anthrax is a serious infectious disease caused by gram-positive, rod-shaped bacteria known as Bacillus anthracis. It occurs naturally in soil and commonly affects domestic and wild animals around the world. People can get sick with anthrax if they come into contact with infected animals or contaminated animal products. The Anthrax Treatment Market is Segmented by Anthrax Type (Cutaneous Anthrax, Inhalation Anthrax, Gastrointestinal Anthrax, and Injection Anthrax), Drug Class (Antibiotics, Immunoglobulins, and Others), Distribution Channel (Hospitals, Pharmacies, and Other Distribution Channels), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
By Anthrax Type | |
Cutaneous Anthrax | |
Inhalation Anthrax | |
Gastrointestinal Anthrax | |
Injection Anthrax |
By Drug Class | |
Antibiotics | |
Immunoglobulins | |
Others |
By Distribution Channel | |
Hospitals | |
Pharmacies | |
Other Distribution Channels |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Anthrax Treatment Market Size Summary
The anthrax treatment market is poised for significant growth, driven by increased research funding and the development of novel therapies. The market's expansion is further supported by the emergence of new anthrax cases in animals, which heightens the risk of human exposure to Bacillus anthracis spores. Despite the challenges posed by the COVID-19 pandemic, which disrupted supply chains and treatment protocols, the market has shown resilience, particularly in developing regions where outbreaks have been more frequent. The reinstatement of supply chains and healthcare facilities post-pandemic is expected to contribute to the market's growth trajectory. Additionally, advancements in treatment options, such as the development of new antibiotics and therapeutic approaches, are anticipated to bolster the market's expansion.
North America is expected to lead the global anthrax treatment market, supported by substantial government funding, strategic initiatives, and the presence of key industry players. Although anthrax is rare in the United States, sporadic outbreaks in animals and occasional human cases underscore the need for effective treatment and prevention measures. The region's market growth is further propelled by collaborations and contracts for the development and supply of anthrax treatments, such as ANTHIM. The market remains fragmented, with numerous companies vying for dominance through innovative therapeutic developments and increased research investments. Key players in the market include Nighthawk Biosciences, Inc., Emergent, Paratek Pharmaceuticals, Inc., and others, all contributing to the competitive landscape and potential growth opportunities in the anthrax treatment sector.
Anthrax Treatment Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increase in Research Funding
-
1.2.2 Development of Novel Therapies for Treatment of Anthrax
-
-
1.3 Market Restraints
-
1.3.1 High Cost Associated with Diagnostic Treatment
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Anthrax Type
-
2.1.1 Cutaneous Anthrax
-
2.1.2 Inhalation Anthrax
-
2.1.3 Gastrointestinal Anthrax
-
2.1.4 Injection Anthrax
-
-
2.2 By Drug Class
-
2.2.1 Antibiotics
-
2.2.2 Immunoglobulins
-
2.2.3 Others
-
-
2.3 By Distribution Channel
-
2.3.1 Hospitals
-
2.3.2 Pharmacies
-
2.3.3 Other Distribution Channels
-
-
2.4 Geography
-
2.4.1 North America
-
2.4.1.1 United States
-
2.4.1.2 Canada
-
2.4.1.3 Mexico
-
-
2.4.2 Europe
-
2.4.2.1 Germany
-
2.4.2.2 United Kingdom
-
2.4.2.3 France
-
2.4.2.4 Italy
-
2.4.2.5 Spain
-
2.4.2.6 Rest of Europe
-
-
2.4.3 Asia Pacific
-
2.4.3.1 China
-
2.4.3.2 Japan
-
2.4.3.3 India
-
2.4.3.4 Australia
-
2.4.3.5 South Korea
-
2.4.3.6 Rest of Asia-Pacific
-
-
2.4.4 Middle East and Africa
-
2.4.4.1 GCC
-
2.4.4.2 South Africa
-
2.4.4.3 Rest of Middle East and Africa
-
-
2.4.5 South America
-
2.4.5.1 Brazil
-
2.4.5.2 Argentina
-
2.4.5.3 Rest of South America
-
-
-
Anthrax Treatment Market Size FAQs
What is the current Anthrax Treatment Market size?
The Anthrax Treatment Market is projected to register a CAGR of 7.80% during the forecast period (2024-2029)
Who are the key players in Anthrax Treatment Market?
Pfizer Inc., Emergent, Nighthawk Biosciences, Inc. (Elusys Therapeutics Inc.), Almirall, LLC and Paratek Pharmaceuticals, Inc. are the major companies operating in the Anthrax Treatment Market.